drugset / Trial / NCT04478526

Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions

NCT04478526

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Generalized anxiety disorder (GAD) is an extremely prevalent and debilitating mental health disorder. Currently, the gold standard treatment for GAD is cognitive behavioural therapy (CBT) and/or pharmacotherapy. The most common medications used to treat GAD are selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). While CBT is a gold standard treatment for GAD, it is costly, time-consuming, and often inaccessible. Fortunately, the electronic delivery of CBT (e-CBT) has emerged as a promising solution to address these barriers. e-CBT has shown to offer comparable results to in-person CBT while improving accessibility for patients and time efficiency for clinicians. The following project aims to investigate the treatment efficacy of e-CBT compared to, and in conjunction with pharmacotherapy for GAD. This study has been designed using a quasi-experimental design to allow patients the freedom to choose which treatment modality they would like to receive. Participants with a diagnosis of GAD will be enrolled in 1 of 3 possible treatment arms: e-CBT, medication, or combination. The e-CBT program will include a 12-week psychotherapy program delivered through the Online Psychotherapy Tool (OPTT), a secure, cloud-based, digital mental health platform. The treatment efficacy of e-CBT will be compared to the treatment efficacy of the medication arm and the combination arm. Conclusions: If e-CBT is shown to either be comparable to medication or that the effects of both treatments are augmented when used in tandem, these findings could have major implications on the mental health care system. e-CBT is a more accessible, and affordable treatment that could increase mental health care capacity by four-folds if proven viable.

Timeline

Start
2020-04-29
Primary completion
2021-05-01
Completion
2021-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule
Subject Buspirone Small molecule
Subject Duloxetine Small molecule
Subject Escitalopram Small molecule
Subject Imipramine Small molecule
Subject Olanzapine Small molecule
Subject Pregabalin Small molecule
Subject Risperidone Other / unclassified
Subject Sertraline Small molecule
Subject Venlafaxine Small molecule
Subject mirtazepine Unknown